

**ENTERED**

November 02, 2023

Nathan Ochsner, Clerk

**IN THE UNITED STATES BANKRUPTCY COURT  
FOR THE SOUTHERN DISTRICT OF TEXAS  
HOUSTON DIVISION**

In re:

Chapter 11

SORRENTO THERAPEUTICS INC., *et al.*<sup>1</sup>

Case No. 23-90085 (CML)

Debtors.


(Jointly Administered)

**ORDER GRANTING SECOND INTERIM FEE APPLICATION  
OF LATHAM & WATKINS LLP FOR COMPENSATION  
FOR SERVICES RENDERED AND FOR REIMBURSEMENT  
OF EXPENSES AS BANKRUPTCY CO-COUNSEL TO THE DEBTORS  
FOR THE PERIOD FROM JUNE 1, 2023 THROUGH AUGUST 31, 2023**

The Court has considered the *Second Interim Application of Latham & Watkins LLP for Compensation for Services Rendered and for Reimbursement of Expenses as Bankruptcy Co-Counsel to the Debtors for the Period from June 1, 2023 through August 31, 2023* filed by Latham & Watkins LLP (the “Applicant”). The Court orders:

1. The Applicant is allowed interim compensation and reimbursement of expenses in the amount of \$8,980,484.85 for the period set forth in the application.
2. The Debtors are authorized to disburse any unpaid amounts allowed by paragraph 1 of this Order.

Signed: November 01, 2023

  
\_\_\_\_\_  
Christopher Lopez  
United States Bankruptcy Judge

<sup>1</sup> The Debtor entities in these chapter 11 cases, along with the last four digits of each Debtor entity’s federal tax identification number, are: Sorrento Therapeutics, Inc. (4842) and Scintilla Pharmaceuticals, Inc. (7956). The Debtors’ service address is: 4955 Directors Place, San Diego, CA 92121.